Health Care
Cencora's Q3 FY2026 results highlighted robust topline and bottom-line growth driven by the OneOncology acquisition and GLP-1 sales, yet rising costs and debt warrant attention.
Key risk: High Financial Leverage
Total long-term debt surged 42.3% year-over-year to $11.7B, with a debt-to-equity ratio of 3.84, increasing interest burden and refinancing risk.
Other Health Care Distributors companies